Age-Related Macular Degeneration Theo dõi

Theo dõi

The frequency of follow-up depends on the type of AMD and the risk of progression. Follow-up at regular intervals is recommended for early detection of asymptomatic and treatable CNV lesions. History documentation and physical examination are recommended every visit. The recommended monitoring examinations during follow-up include mononuclear near vision (using Amsler grid) monitoring, visual acuity assessment at distance with correction, and stereoscopic biomicroscopic examination of the fundus. Patients treated with intravitreal anti-VEGF agents or who underwent PDT with Verteporfin or thermal laser photocoagulation surgery should undergo biomicroscopy of the fundus, OCT, OCTA, FFA, and fundus photography at regular intervals for earlier detection of signs of active exudation or disease progression.  

Schedule of Follow-up  

For non-neovascular early AMD or advanced AMD with bilateral subfoveal geographic atrophy or disciform scars under observation, follow-up examination with fundus photography, FFA, OCT or OCTA is done at 6 to 24 months if asymptomatic. However, immediate follow-up is advised if new symptoms of CNV occur.  

For non-neovascular intermediate or advanced AMD in antioxidant vitamin and mineral supplements, follow-up is at 6 to 18 months after treatment if asymptomatic. If there are new symptoms suggestive of CNV, immediate consultation is advised.  

Those with subfoveal neovascular AMD in Aflibercept, Bevacizumab, Brolicizumab or Ranibizumab therapy, follow-up is at approximately 4 weeks after treatment. Subsequent follow-up is based on clinical findings.

For those with subfoveal neovascular AMD in Pegaptanib sodium therapy, follow-up is every 6 weeks with retreatments as indicated. For those with subfoveal neovascular AMD treated with PDT with Verteporfin, follow-up is at every 3 months until stable, with retreatments as indicated.  Lastly, those with extrafoveal neovascular AMD after laser photocoagulation therapy, follow-up is at 2 to 4 weeks after treatment with FFA and then 4 to 6 weeks thereafter based on clinical and angiographic findings.